9 results on '"Bernstein, Jonine"'
Search Results
2. Association of breast cancer with MRI background parenchymal enhancement: the IMAGINE case-control study.
- Author
-
Buys, Saundra, Bradbury, Angela, Brooks, Jennifer, Conant, Emily, Weinstein, Susan, Kontos, Despina, Woods, Meghan, Colonna, Sarah, Liang, Xiaolin, Stein, Matthew, Pike, Malcolm, Bernstein, Jonine, Watt, Gordon, Sung, Janice, and Morris, Elizabeth
- Subjects
Background parenchymal enhancement ,Breast cancer ,Case-control study ,Magnetic resonance imaging ,Risk factors ,Adult ,Aged ,Breast ,Breast Density ,Breast Neoplasms ,Case-Control Studies ,Contrast Media ,Female ,Follow-Up Studies ,Humans ,Magnetic Resonance Imaging ,Mass Screening ,Middle Aged ,Predictive Value of Tests ,Retrospective Studies ,Risk Assessment ,Risk Factors ,Young Adult - Abstract
BACKGROUND: Background parenchymal enhancement (BPE) on breast magnetic resonance imaging (MRI) may be associated with breast cancer risk, but previous studies of the association are equivocal and limited by incomplete blinding of BPE assessment. In this study, we evaluated the association between BPE and breast cancer based on fully blinded assessments of BPE in the unaffected breast. METHODS: The Imaging and Epidemiology (IMAGINE) study is a multicenter breast cancer case-control study of women receiving diagnostic, screening, or follow-up breast MRI, recruited from three comprehensive cancer centers in the USA. Cases had a first diagnosis of unilateral breast cancer and controls had no history of or current breast cancer. A single board-certified breast radiologist with 12 years experience, blinded to case-control status and clinical information, assessed the unaffected breast for BPE without view of the affected breast of cases (or the corresponding breast laterality of controls). The association between BPE and breast cancer was estimated by multivariable logistic regression separately for premenopausal and postmenopausal women. RESULTS: The analytic dataset included 835 cases and 963 controls. Adjusting for fibroglandular tissue (breast density), age, race/ethnicity, BMI, parity, family history of breast cancer, BRCA1/BRCA2 mutations, and other confounders, moderate/marked BPE (vs minimal/mild BPE) was associated with breast cancer among premenopausal women [odds ratio (OR) 1.49, 95% CI 1.05-2.11; p = 0.02]. Among postmenopausal women, mild/moderate/marked vs minimal BPE had a similar, but statistically non-significant, association with breast cancer (OR 1.45, 95% CI 0.92-2.27; p = 0.1). CONCLUSIONS: BPE is associated with breast cancer in premenopausal women, and possibly postmenopausal women, after adjustment for breast density and confounders. Our results suggest that BPE should be evaluated alongside breast density for inclusion in models predicting breast cancer risk.
- Published
- 2020
3. Association of breast cancer with MRI background parenchymal enhancement: the IMAGINE case-control study
- Author
-
Watt, Gordon P., Sung, Janice, Morris, Elizabeth A., Buys, Saundra S., Bradbury, Angela R., Brooks, Jennifer D., Conant, Emily F., Weinstein, Susan P., Kontos, Despina, Woods, Meghan, Colonna, Sarah V., Liang, Xiaolin, Stein, Matthew A., Pike, Malcolm C., and Bernstein, Jonine L.
- Published
- 2020
- Full Text
- View/download PDF
4. Study design: Evaluating gene–environment interactions in the etiology of breast cancer – the WECARE study
- Author
-
Bernstein, Jonine L, Langholz, Bryan, Haile, Robert W, Bernstein, Leslie, Thomas, Duncan C, Stovall, Marilyn, Malone, Kathleen E, Lynch, Charles F, Olsen, Jørgen H, Anton-Culver, Hoda, Shore, Roy E, Boice, John D, Berkowitz, Gertrud S, Gatti, Richard A, Teitelbaum, Susan L, Smith, Susan A, Rosenstein, Barry S, Børresen-Dale, Anne-Lise, Concannon, Patrick, and Thompson, W Douglas
- Subjects
Clinical Research ,Breast Cancer ,Cancer ,Prevention ,Genetics ,Genetic Testing ,2.1 Biological and endogenous factors ,Aetiology ,2.2 Factors relating to the physical environment ,Adult ,Alleles ,Ataxia Telangiectasia Mutated Proteins ,Breast Neoplasms ,Case-Control Studies ,Cell Cycle Proteins ,Cocarcinogenesis ,DNA-Binding Proteins ,Female ,Genes ,BRCA1 ,Genes ,BRCA2 ,Genes ,Tumor Suppressor ,Genetic Predisposition to Disease ,Genotype ,Humans ,Likelihood Functions ,Middle Aged ,Neoplasms ,Radiation-Induced ,Neoplasms ,Second Primary ,Phantoms ,Imaging ,Protein Serine-Threonine Kinases ,Radiotherapy ,Radiotherapy Dosage ,Registries ,Research Design ,Single-Blind Method ,Tumor Suppressor Proteins ,bilateral breast cancer ,breast cancer susceptibility genes ,counter-matching ,gene-environment interactions ,radiation dosimetry ,study design ,WECARE study ,Oncology and Carcinogenesis ,Oncology & Carcinogenesis - Abstract
IntroductionDeficiencies in cellular responses to DNA damage can predispose to cancer. Ionizing radiation can cause cluster damage and double-strand breaks (DSBs) that pose problems for cellular repair processes. Three genes (ATM, BRCA1, and BRCA2) encode products that are essential for the normal cellular response to DSBs, but predispose to breast cancer when mutated.DesignTo examine the joint roles of radiation exposure and genetic susceptibility in the etiology of breast cancer, we designed a case-control study nested within five population-based cancer registries. We hypothesized that a woman carrying a mutant allele in one of these genes is more susceptible to radiation-induced breast cancer than is a non-carrier. In our study, 700 women with asynchronous bilateral breast cancer were individually matched to 1400 controls with unilateral breast cancer on date and age at diagnosis of the first breast cancer, race, and registry region, and counter-matched on radiation therapy. Each triplet comprised two women who received radiation therapy and one woman who did not. Radiation absorbed dose to the contralateral breast after initial treatment was estimated with a comprehensive dose reconstruction approach that included experimental measurements in anthropomorphic and water phantoms applying patient treatment parameters. Blood samples were collected from all participants for genetic analyses.ConclusionsOur study design improves the potential for detecting gene-environment interactions for diseases when both gene mutations and the environmental exposures of interest are rare in the general population. This is particularly applicable to the study of bilateral breast cancer because both radiation dose and genetic susceptibility have important etiologic roles, possibly by interactive mechanisms. By using counter-matching, we optimized the informativeness of the collected dosimetry data by increasing the variability of radiation dose within the case-control sets and enhanced our ability to detect radiation-genotype interactions.
- Published
- 2004
5. The association of mammographic density with risk of contralateral breast cancer and change in density with treatment in the WECARE study
- Author
-
Knight, Julia A., Blackmore, Kristina M., Fan, Jing, Malone, Kathleen E., John, Esther M., Lynch, Charles F., Vachon, Celine M., Bernstein, Leslie, Brooks, Jennifer D., Reiner, Anne S., Liang, Xiaolin, Woods, Meghan, WECARE Study Collaborative Group, and Bernstein, Jonine L.
- Published
- 2018
- Full Text
- View/download PDF
6. Hormone receptor status of a first primary breast cancer predicts contralateral breast cancer risk in the WECARE study population.
- Author
-
Reiner, Anne S., Lynch, Charles F., Sisti, Julia S., John, Esther M., Brooks, Jennifer D., Bernstein, Leslie, Knight, Julia A., Li Hsu, Concannon, Patrick, Mellemkjær, Lene, Tischkowitz, Marc, Haile, Robert W., Ronglai Shen, Malone, Kathleen E., Woods, Meghan, Xiaolin Liang, Morrow, Monica, Bernstein, Jonine L., Hsu, Li, and Shen, Ronglai
- Subjects
BREAST cancer ,HORMONE receptors ,ESTROGEN receptors ,PROGESTERONE receptors ,POPULATION-based case control ,BREAST tumor diagnosis ,BREAST tumor treatment ,PROTEIN metabolism ,ANTHROPOMETRY ,BREAST tumors ,CELL receptors ,COMPARATIVE studies ,REPORTING of diseases ,RESEARCH methodology ,MEDICAL cooperation ,GENETIC mutation ,PROTEINS ,PUBLIC health surveillance ,RESEARCH ,RESEARCH funding ,TUMOR classification ,EVALUATION research ,CASE-control method ,TUMOR grading - Abstract
Background: Previous population-based studies have described first primary breast cancer tumor characteristics and their association with contralateral breast cancer (CBC) risk. However, information on influential covariates such as treatment, family history of breast cancer, and BRCA1/2 mutation carrier status was not available. In a large, population-based, case-control study, we evaluated whether tumor characteristics of the first primary breast cancer are associated with risk of developing second primary asynchronous CBC, overall and in subgroups of interest, including among BRCA1/2 mutation non-carriers, women who are not treated with tamoxifen, and women without a breast cancer family history.Methods: The Women's Environmental Cancer and Radiation Epidemiology Study is a population-based case-control study of 1521 CBC cases and 2212 individually-matched controls with unilateral breast cancer. Detailed information about breast cancer risk factors, treatment for and characteristics of first tumors, including estrogen receptor (ER) and progesterone receptor (PR) status, was obtained by telephone interview and medical record abstraction. Multivariable risk ratios (RRs) and 95% confidence intervals (CIs) were estimated in conditional logistic regression models, adjusting for demographics, treatment, and personal medical and family history. A subset of women was screened for BRCA1/2 mutations.Results: Lobular histology of the first tumor was associated with a 30% increase in CBC risk (95% CI 1.0-1.6). Compared to women with ER+/PR+ first tumors, those with ER-/PR- tumors had increased risk of CBC (RR = 1.4, 95% CI 1.1-1.7). Notably, women with ER-/PR- first tumors were more likely to develop CBC with the ER-/PR- phenotype (RR = 5.4, 95% CI 3.0-9.5), and risk remained elevated in multiple subgroups: BRCA1/2 mutation non-carriers, women younger than 45 years of age, women without a breast cancer family history, and women who were not treated with tamoxifen.Conclusions: Having a hormone receptor negative first primary breast cancer is associated with increased risk of CBC. Women with ER-/PR- primary tumors were more likely to develop ER-/PR- CBC, even after excluding BRCA1/2 mutation carriers. Hormone receptor status, which is routinely evaluated in breast tumors, may be used clinically to determine treatment protocols and identify patients who may benefit from increased surveillance for CBC. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
7. Systemic therapy for breast cancer and risk of subsequent contralateral breast cancer in the WECARE Study.
- Author
-
Langballe, Rikke, Mellemkjær, Lene, Malone, Kathleen E., Lynch, Charles F., John, Esther M., Knight, Julia A., Bernstein, Leslie, Brooks, Jennifer, Andersson, Michael, Reiner, Anne S., Liang, Xiaolin, Woods, Meghan, Concannon, Patrick J., Bernstein, Jonine L., and WECARE Study Collaborative Group
- Subjects
BREAST cancer risk factors ,BREAST cancer treatment ,CANCER chemotherapy ,MEDICAL records ,TAMOXIFEN ,ANTINEOPLASTIC agents ,BREAST tumors ,PUBLIC health surveillance ,RESEARCH funding ,RISK assessment ,CASE-control method ,SECONDARY primary cancer ,ODDS ratio - Abstract
Background: Treatment with tamoxifen or chemotherapy reduces the risk of contralateral breast cancer (CBC). However, it is uncertain how long the protection lasts and whether the protective effect is modified by patient, tumor, or treatment characteristics.Methods: The population-based WECARE Study included 1521 cases with CBC and 2212 age- and year of first diagnosis-matched controls with unilateral breast cancer recruited during two phases in the USA, Canada, and Denmark. Women were diagnosed with a first breast cancer before age 55 years during 1985-2008. Abstraction of medical records provided detailed treatment information, while information on risk factors was obtained during telephone interviews. Risk ratios (RRs) and 95 % confidence intervals (CIs) for CBC were obtained from multivariable conditional logistic regression models.Results: Compared with never users of tamoxifen, the RR of CBC was lower for current users of tamoxifen (RR = 0.73; 95 % CI = 0.55-0.97) and for past users within 3 years of last use (RR = 0.73; 95 % CI = 0.53-1.00). There was no evidence of an increased risk of estrogen receptor-negative CBC associated with ever use of tamoxifen or use for 4.5 or more years. Use of chemotherapy (ever versus never use) was associated with a significantly reduced RR of developing CBC 1-4 years (RR = 0.59; 95 % CI = 0.45-0.77) and 5-9 years (RR = 0.73; 95 % CI = 0.56-0.95) after first breast cancer diagnosis. RRs of CBC associated with tamoxifen or with chemotherapy use were independent of age, family history of breast cancer, body mass index and tumor characteristics of the first breast cancer with the exception that the RR of CBC was lower for lobular histology compared with other histologies.Conclusion: Our findings are consistent with previous studies showing that treatment with tamoxifen or chemotherapy is associated with a lower risk of CBC although the risk reduction appears to last for a limited time period after treatment is completed. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
8. Workshop on The Epidemiology of the ATMGene: Impact on Breast Cancer Risk and Treatment, Present Status and Future Focus, Lillehammer, Norway, 29 June 2002
- Author
-
Bernstein, Jonine L, primary, Seminara, Daniela, additional, and Børresen-Dale, Anne-Lise, additional
- Published
- 2002
- Full Text
- View/download PDF
9. CYP2D6 phenotype, tamoxifen, and risk of contralateral breast cancer in the WECARE Study.
- Author
-
Brooks, Jennifer D., Comen, Elizabeth A., Reiner, Anne S., Orlow, Irene, Leong, Siok F., Liang, Xiaolin, Mellemkjær, Lene, Knight, Julia A., Lynch, Charles F., John, Esther M., Bernstein, Leslie, Woods, Meghan, Doody, David R., Malone, Kathleen E., Bernstein, Jonine L., and WECARE Study collaborative group
- Subjects
GERM cells ,TAMOXIFEN ,BREAST cancer ,LOGISTIC regression analysis - Abstract
Background: Tamoxifen treatment greatly reduces a woman's risk of developing a second primary breast cancer. There is, however, substantial variability in treatment response, some of which may be attributed to germline genetic variation. CYP2D6 is a key enzyme in the metabolism of tamoxifen to its active metabolites, and variants in this gene have been associated with reduced tamoxifen metabolism. The impact of variation on risk of contralateral breast cancer (CBC) is unknown.Methods: Germline DNA from 1514 CBC cases and 2203 unilateral breast cancer controls was genotyped for seven single nucleotide polymorphisms, one three-nucleotide insertion-deletion, and a full gene deletion. Each variant has an expected impact on enzyme activity, which in combination allows for the classification of women as extensive, intermediate, and poor metabolizers (EM, IM, and PM respectively). Each woman was assigned one of six possible diplotypes and a corresponding CYP2D6 activity score (AS): EM/EM (AS = 2), EM/IM (AS = 1.5), EM/PM (AS = 1), IM/IM (AS = 0.75), IM/PM (AS = 0.5), and PM/PM (AS = 0). We also collapsed categories of the AS to generate an overall phenotype (EM, AS ≥ 1; IM, AS = 0.5-0.75; PM, AS = 0). Rate ratios (RRs) and 95% confidence intervals (CIs) for the association between tamoxifen treatment and risk of CBC in our study population were estimated using conditional logistic regression, stratified by AS.Results: Among women with AS ≥ 1 (i.e., EM), tamoxifen treatment was associated with a 20-55% reduced RR of CBC (AS = 2, RR = - 0.81, 95% CI 0.62-1.06; AS = 1.5, RR = 0.45, 95% CI 0.30-0.68; and AS = 1, RR = 0.55, 95% CI 0.40-0.74). Among women with no EM alleles and at least one PM allele (i.e., IM and PM), tamoxifen did not appear to impact the RR of CBC in this population (AS = 0.5, RR = 1.08, 95% CI 0.59-1.96; and AS = 0, RR = 1.17, 95% CI 0.58-2.35) (p for homogeneity = - 0.02).Conclusion: This study suggests that the CYP2D6 phenotype may contribute to some of the observed variability in the impact of tamoxifen treatment for a first breast cancer on risk of developing CBC. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.